<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03068247</url>
  </required_header>
  <id_info>
    <org_study_id>MH108534</org_study_id>
    <nct_id>NCT03068247</nct_id>
  </id_info>
  <brief_title>Neurobiology of Treatment Responses in MDD</brief_title>
  <official_title>Neurobiology of Non-Specific and Specific Treatment Responses in Major Depression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Utah</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Utah</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary study intent is to examine biological mechanisms associated with acute and&#xD;
      chronic treatment responses in major depressive disorder (MDD). It is hypothesized that&#xD;
      treatment responsiveness, representing endogenous opioid system function, will be associated&#xD;
      with acute improvements in mood state over a 10-week treatment trial in MDD. Potential (bio)&#xD;
      markers of treatment effects will be tested against psychophysical responses to placebo and&#xD;
      active treatments.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Volunteers will be randomized to receive placebo pills or a commercially available SNRI for&#xD;
      10 weeks. Volunteers will undergo imaging with structural and functional MRI and PET with&#xD;
      [11C]carfentanil to determine baseline μOR BPND and changes in BPND measures during acute&#xD;
      i.v. medication administration at the time of scanning before and after the 10-week treatment&#xD;
      period.&#xD;
&#xD;
      To elicit the activation of µ-opioid-mediated neurotransmission in the scanner, we utilize&#xD;
      the introduction of medication (active or inactive) 1mL into an intravenous port every 4&#xD;
      minutes, 15 sec per infusion, starting 45 minutes after radiotracer administration, until&#xD;
      scan completion. Participants are made aware that the study drug will be administered at the&#xD;
      time a computer-generated human voice recording reads a second-by-second count of the&#xD;
      infusion timing (15 sec).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 2021</start_date>
  <completion_date type="Anticipated">May 2023</completion_date>
  <primary_completion_date type="Anticipated">May 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>mu-opioid receptor binding capacity</measure>
    <time_frame>10 weeks</time_frame>
    <description>derived from PET scans</description>
  </primary_outcome>
  <primary_outcome>
    <measure>depression score</measure>
    <time_frame>10 weeks</time_frame>
    <description>HRSD-17 score</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Major Depressive Disorder</condition>
  <arm_group>
    <arm_group_label>Interventional</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 weeks of duloxetine beginning at 30 mg per day for week 1, then 60 mg / day thereafter.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>10 weeks of placebo once daily for 1 week, then twice daily therafter.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Duloxetine</intervention_name>
    <description>10 week treatment</description>
    <arm_group_label>Interventional</arm_group_label>
    <other_name>Cymbalta</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>10 week treatment</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Meet DSM V criteria for Major Depressive Episode, single episode or recurrent, for at&#xD;
             least a month;&#xD;
&#xD;
          -  Unmedicated for at least 10 half-lives of the previous AD used;&#xD;
&#xD;
          -  Willing to limit the introduction of any new treatments during the study;&#xD;
&#xD;
          -  18 - 55 years of age;&#xD;
&#xD;
          -  Right handed;&#xD;
&#xD;
          -  Capable of giving written informed consent;&#xD;
&#xD;
          -  Hamilton Depression Rating Scale (17-item HDRS, not including atypical features) &gt;15&#xD;
             at screening and randomization;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Major medical illness (e.g., cancer, HIV, Hepatitis C, etc.) or concurrent, untreated,&#xD;
             or symptomatic medical illnesses, including acute or ongoing pain, autoimmune or&#xD;
             inflammatory disease;&#xD;
&#xD;
          -  Use of narcotic analgesics within the last 6 months or regular use of sleeping aids&#xD;
             (including benzodiazepines and related compounds), more than twice a week;&#xD;
&#xD;
          -  Recent history of substance abuse (within the last 6 months) or history of substance&#xD;
             dependence (lifetime);&#xD;
&#xD;
          -  Other comorbid psychiatric illnesses, such as Bipolar Disorder, Obsessive Compulsive&#xD;
             Disorder, Panic Disorder, any psychosis, or Axis II diagnoses. Generalized Anxiety and&#xD;
             Social Anxiety Disorders will NOT be considered exclusionary given their common&#xD;
             association with MDD&#xD;
&#xD;
          -  Concurrent participation in other therapeutic trials;&#xD;
&#xD;
          -  Pregnancy/nursing;&#xD;
&#xD;
          -  Ongoing treatment with medications with psychotropic properties;&#xD;
&#xD;
          -  Contraindications to PET or MRI methods;&#xD;
&#xD;
          -  Impairments, activities or situations that would prevent completion of the study&#xD;
             protocol;&#xD;
&#xD;
          -  Prior non-response to duloxetine;&#xD;
&#xD;
          -  Active suicidal ideation.&#xD;
&#xD;
          -  Urine screens positive for opioids or any substances of abuse.&#xD;
&#xD;
          -  Allergy to fentanyl (because of structural similarity to the radiotracer&#xD;
             [11C]carfentanil to be employed in the study).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Chandni Sheth, PhD</last_name>
    <phone>8015871622</phone>
    <email>Chandni.sheth@utah.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Allison Bustamante</last_name>
    <phone>8017421517</phone>
    <email>utahneuroimagelab@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Chandni Sheth, PhD</last_name>
      <phone>801-587-1622</phone>
      <email>chandni.sheth@utah.edu</email>
    </contact>
    <contact_backup>
      <last_name>Allison Bustamante</last_name>
      <phone>8017421517</phone>
      <email>utahneuroimagelab@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>February 24, 2017</study_first_submitted>
  <study_first_submitted_qc>February 24, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 1, 2017</study_first_posted>
  <last_update_submitted>April 21, 2021</last_update_submitted>
  <last_update_submitted_qc>April 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Duloxetine Hydrochloride</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

